Citations

Clear

13603 citation(s) found for "_, _".

Aggressive non-Hodgkin and Burkitt lymphomas
Rosenthal, Allison , Rosenthal, Allison

Mayo Clinic

American Society of Hematology Self-Assessment Program, Ninth Edition | June 30, 2025 | Volume: No volume available | Issue: No issue available | Pages: 552-565

10.1182/ashsap9.chapter45 Get It

Next-Generation Approaches in Sports Medicine: The Role of Genetics, Omics, and Digital Health in Optimizing Athlete Performance and Longevity—A Narrative Review
Juginović, Alen , Kekić, Adrijana, Aranza, Ivan , Biloš, Valentina, Armanda, Mirko, Armanda, Mirko

Mayo Clinic

Life | June 30, 2025 | Volume: 15 | Issue: 7 | Pages: 1023

10.3390/life15071023 | PMID 40724525 Get It

This review aims to provide a comprehensive framework for implementing precision sports medicine, integrating genetics, pharmacogenomics, digital health solutions, and multi-omics data. Literature review was conducted using MEDLINE, EMBASE, Web of Science, and Cochrane Library databases (January 2018–April 2024), focusing on precision medicine applications in sports medicine, utilizing key terms including “precision medicine”, “sports medicine”, “genetics”, and “multi-omics”, with forward and backward citation tracking. The review identified key gene variants affecting athletic performance: endurance (AMPD1, PPARGC1A), power (ACTN3, NOS3), strength (PPARG), and injury susceptibility (COL5A1, MMP3), while also examining inherited conditions like cardiomyopathies (MYH7, MYBPC3). Pharmacogenomic guidelines were established for optimizing common sports medications, including NSAIDs (CYP2C9), opioids (CYP2D6), and cardiovascular drugs (SLCO1B1, CYP2C19). Digital health technologies, including wearables and predictive analytics, showed potential for enhanced athlete monitoring and injury prevention, while multi-omics approaches integrated various molecular data to understand exercise capacity and injury predisposition, enabling personalized assessments, training regimens, and therapeutic interventions based on individual biomolecular profiles. This review provides sports medicine professionals with a framework to deliver personalized care tailored to each athlete’s unique profile, promising optimized performance, reduced injury risks, and improved recovery outcomes.
The Traumatic Brain Injury-Alzheimer’s Disease and Alzheimer’s Disease-related Dementia Caregiver Support Intervention: A Mixed Methods Evaluation of Program Feasibility, Acceptability, and Utility
Wilson, Mary Ann , Birkeland, Robyn , Albers, Elizabeth , Louwagie, Katie , Finn, Jacob A. , Ostenso, Samantha , Gaugler, Joseph E. , Chesak, Sherry S. , Gaugler, Joseph E , Wilson, Mara, Ratner, Edward R.

Mayo Clinic

Innovation in Aging | June 27, 2025 | Volume: 9 | Issue: 6 | Pages: No page available

10.1093/geroni/igaf057 | PMID 40709322 Get It

Abstract Background and Objectives Research has established that unpaid family members, friends, or others who care for persons with dementia (ie, caregivers) may encounter socioemotional and physical health concerns as a consequence of providing extensive assistance. Similarly, caregivers for people living with traumatic brain injury (TBI) often experience a range of stressors and negative mental health outcomes due to care demands. Individuals with TBI often develop Alzheimer’s disease and Alzheimer’s disease-related dementia (AD/ADRD). This history of TBI may introduce complications to AD/ADRD caregiving. A comprehensive intervention grounded in the understanding of the complex caregiving context of both diagnoses is warranted to address the unique needs and concerns of TBI-AD/ADRD caregivers. Research Design and Methods This study evaluated the feasibility of the TBI-AD/ADRD Caregiver Support Intervention (TACSI) psychoeducational program, designed to support the unique subset of caregivers facing the challenge of assisting relatives with AD/ADRD and a history of TBI. TACSI, a 6-session telehealth intervention, provides tailored psychosocial and psychoeducational coaching. In partnership with the 2 national healthcare centers, 15 caregivers enrolled in the 3-month feasibility study evaluating the design and subsequent refinement of TACSI. Mixed methods data were collected from 3-month follow-up surveys and qualitative data from postintervention interviews. Results The feasibility, utility, and acceptance of TACSI were established. Caregivers liked the telehealth delivery and the personalized nature of TACSI, yet some expressed it would have been more beneficial earlier in their caregiving journey. Discussion and Implications Caregivers valued the TACSI program. Their feedback has been applied to improve TACSI content and delivery for a larger pilot randomized controlled trial that is currently underway.
Deep endometriosis demystified: Natural progression, hormonal treatment, and malignant transformation
Green, Isabel C. , Stewart, Kelsey A, Stewart, Kelsey A. , Cope, Adela G. , Burnett, Tatnai L.

Mayo Clinic

Current Opinion in Obstetrics & Gynecology | June 27, 2025 | Volume: 37 | Issue: 4 | Pages: 221-232

10.1097/gco.0000000000001036 | PMID 40304250 Get It

Purpose of review We present a review of the natural progression, response to hormonal therapy, and risk of malignancy associated with deep endometriosis (DE) to guide evidence-based discussion of conservative treatment. Recent findings Advanced imaging protocols have enhanced nonsurgical detection of DE, allowing noninvasive diagnosis, treatment, and surveillance. While some DE is progressive, 50% of disease appears stable over time, and progression is reduced by half with hormonal treatments (21 versus 12%). Hormonal treatment can reduce the size of DE lesions by 1 cm³, with reductions occurring after 6 months and remaining stable up to 3 years. Most hormonal therapies improve symptoms and quality of life, regardless of changes in DE size, with combined contraceptives and progestins being the most studied. DE may present a higher risk of ovarian and extraovarian cancer than previously hypothesized, though further research is needed to confirm findings. Limitations of DE research include differing imaging strategies, definitions of disease and progression, short follow-up, focus on rectosigmoid DE only, and lack of randomized trials. Summary DE is a subtype of endometriosis that is increasingly diagnosed and treated with noninvasive strategies. Hormonal treatments improve symptoms and reduce progression of DE. Further research on optimal conservative management and risk of malignancy is warranted.
Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma
Breen, William G. , Anderson, S. Keith , Brown, Paul D. , Yan, Elizabeth , Kizilbash, Sani H. , Anderson, Daniel M. , Tran, David , Mazurczak, Miroslaw, Geoffroy, Francois J., Leinweber, Clinton, Dixon, Jesse G. , Anderson, S Keith , Yan, Elizabeth S, Kizilbash, Sani, Galanis, Eva, Kizilbash, Sani H , Sarkaria, Jann N. , Galanis, Evanthia , Tran, David D. , Johnson, Derek R. , Laack, Nadia N.

Mayo Clinic

Neuro-Oncology | June 27, 2025 | Volume: 27 | Issue: 10 | Pages: 2661-2670

10.1093/neuonc/noaf156 | PMID 40579995 Get It

Abstract Background Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity. Methods North Central Cancer Treatment Group N0877 is a phase 1 dose escalation and phase II randomized study evaluating the maximum tolerated dose (MTD), safety, and efficacy of dasatinib with radiation and temozolomide (TMZ) for glioblastoma. Following identification of the MTD, adult patients with a histologic diagnosis of glioblastoma were randomized 2:1 between dasatinib given with standard concurrent and adjuvant TMZ, versus placebo with standard concurrent and adjuvant TMZ. Radiation dose was 60 Gy in 30 fractions. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), toxicity, and quality of life. Results Thirteen patients were enrolled in the phase I component and established the MTD and phase II dose of 150 mg given daily. A total of 204 patients were enrolled in the phase II component. OS was not different between arms (median OS 15.6 months for dasatinib compared to 19.3 months for placebo, hazard ratio:1.21 favoring placebo, 95% CI: 0.88–1.65, log-rank P-value: .238). Similarly, PFS was not significantly different between the dasatinib and placebo arms. There was a significant increase in anemia, nausea, and creatinine elevation with dasatinib, but significantly more grade 3 lymphopenia with placebo. Conclusions The addition of dasatinib to standard chemoradiation did not improve outcomes for patients with glioblastoma. Clinical Trial Identifier NCT00869401.
Humans with obesity exhibit impaired circulating total, but not free, IGF‐1 response to acute endurance exercise
Freitas, Eduardo D. S. , Roust, Lori R., Filippis, Eleanna De , Brown, Brenna, Katsanos, Christos S. , Brown, Brooke, Katsanos, Christos S , Buras, Matthew

Mayo Clinic

Physiological Reports | June 27, 2025 | Volume: 13 | Issue: 12 | Pages: No page available

10.14814/phy2.70436 | PMID 40574473 Get It

AbstractWe investigated how obesity impacts the response of circulating insulin‐like growth factor‐1 (IGF‐1) to a single bout of endurance exercise in humans with and without obesity. Blood samples were collected before exercise, at 15 and 40 min during a 45‐min cycling session at 65% of heart rate reserve, and 15 min post‐exercise. Serum levels of total IGF‐1, free IGF‐1, IGF binding proteins 1 (IGFBP‐1) and 3 (IGFBP‐3), growth hormone, and insulin were measured. Both total IGF‐1 and IGFBP‐3 serum concentrations increased significantly (p < 0.05) during exercise in the study participants without obesity but not in those with obesity, returning to basal levels immediately after exercise. There was a statistically significant main effect on the growth hormone response, with circulating levels being higher in participants without obesity (p < 0.05). No significant effects were observed for either free IGF‐1 or IGFBP‐1 serum concentrations in response to exercise in either group (p > 0.05). We conclude that humans with obesity have blunted serum total IGF‐1 response during exercise. However, a concurrent attenuation in serum IGFBP‐3 response, which regulates free (i.e., biologically active) IGF‐1 in circulation, results in no change in circulating free IGF‐1 levels during endurance exercise in individuals with obesity.
921 A Rare Occurrence of Three Primary Malignancies of the Rectum, Kidney and Pancreas in a Same Patient: A Case Report
Akhtar, M A B, Aimon, Sibgha , Syed, Aamir Ali , Kazim, Sayed Moosa, Ahmad, T, Akhtar, M H B

Mayo Clinic

British Journal of Surgery | June 27, 2025 | Volume: 112 | Issue: Supplement_10 | Pages: No page available

10.1093/bjs/znaf128.416 Get It

Abstract Introduction Multiple Primary Malignancies (MPMs) are characterized by the presence of at least two distinct primary malignancies in a patient. The occurrence rate of MPMs is between 1.63% and 10.9% across articles. To our knowledge, this combination of tumours has not been documented in the existing literature. Case: A 44-year-old male, presented with complaints of abdominal pain, chronic constipation, and multiple episodes of bleeding per rectum for one month. Colonoscopy showed proliferative irregular growth at junction of recto-sigmoid colon; Biopsy showed well-differentiated adenocarcinoma. CT scan abdomen and MRI pelvis showed focal eccentric thickening at the rectosigmoid region and enhancing, partly exophytic left renal mass 3.6 x 2.2 x 2.0 cm from the lower pole, another exophytic soft tissue nodule 2.2 x 1.6 x 1.9 cm on inferior surface of body of pancreas. The biopsy of pancreatic mass was neuroendocrine tumour WHO grade 1. KRAS, BRAF, and MSI were negative. A multidisciplinary team discussion was done, and patient underwent laparoscopic-assisted low anterior resection, open left partial nephrectomy, and enucleation of the pancreatic mass in a single setting. The postoperative course remained uneventful. Histopathology showed rectosigmoid tumour: moderately differentiated mucinous adenocarcinoma, 3/19 lymph nodes positive for metastatic carcinoma. Renal tumour Histopathology: 28mm clear cell renal carcinoma. Pancreatic tumour histopathology: solid pseudopapillary neoplasm. All resection margins free of tumour. He received 4 cycles of adjuvant chemotherapy and now he is on surveillance. Conclusions The occurrence of synchronous triple primary malignancies presents a complex clinical challenge and requires meticulous diagnostic evaluation, multidisciplinary collaboration, and personalized treatment strategies.
Curative Treatment of Pediatric Hodgkin Lymphoma With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Consolidation Radiotherapy: A Systematic Review and Suggested Recommendations
Hernández-Benítez, Josué , López-Azcarraga, Alejandra , Flerlage, Jamie E. , Castellino, Sharon M. , Aristizabal, Paula , Milgrom, Sarah A. , Paula, Mario José Aguiar de, Vega, Raymond B. Mailhot , Castellino, Sharon , Milgrom, Sarah , Mailhot Vega, Raymond B , Flerlage, Jamie E , Hernandez-Benitez, Josue A. , Hoppe, Bradford S. , Paula, Mario José Aguiar de

Mayo Clinic

JCO Global Oncology | June 26, 2025 | Volume: No volume available | Issue: 11 | Pages: No page available

10.1200/go-24-00485 | PMID 40570263 Get It

PURPOSE Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy is used commonly for pediatric Hodgkin lymphoma (pHL) in low- and middle-income countries. The role of radiotherapy (RT) after ABVD in pHL is uncertain. MATERIALS AND METHODS We conducted a systematic review to explore the use of ABVD with or without RT in pHL. Key clinical questions included the number of cycles of ABVD, indications for and dose of RT, and outcomes by risk group. A search was performed in PubMed. Articles reporting survival outcomes by risk group were included. RESULTS Of 97 articles identified in the literature search, nine met inclusion criteria. Chemotherapy consisted of four to six cycles in limited disease and mostly six cycles in advanced disease. Three studies used RT for all patients within a specified risk group. Six studies dictated an adapted RT approach, with 3%-43% of the patients receiving RT for bulky adenopathy, slow early response (SER), and/or incomplete response. Radiation doses ranged between 20 and 36 Gy. The progression-free survival and overall survival at 4-10 years ranged from 84% to 100% and 93%-100% in limited disease and 50%-84.4% and 75%-95.3% in advanced disease, respectively. Studies did not directly assess the impact of certain chemotherapy or RT strategies. Recommendations were made after reviewing outcomes with particular approaches. CONCLUSION Four cycles of ABVD are recommended for limited disease, and six cycles of ABVD are recommended for advanced disease. In both limited and advanced diseases, RT is recommended with a dose of 20-21 Gy only to sites of bulky and/or SER, with a boost of up to 36 Gy to sites of incomplete response. This approach could spare radiation for at least half of the patients with limited disease and one third of advanced disease.
Foam sclerotherapy for symptomatic cysts in ADPKD, ADPLD and solitary cysts
Neidert, Newton B. , Kseibi, Firas, Martin, William P. , Bugazia, Seif, Bendel, Emily C. , Howe, Cassie, Helland, Ryan, Gregory, Adriana , Liestikow, Kathleen, Kline, Timothy L. , Vaughan, Lisa E. , Hogan, Marie C. , Neidert, Newton, Kline, Timothy, Hogan, Marie C , Torres, Vicente E.

Mayo Clinic

Nephrology Dialysis Transplantation | June 26, 2025 | Volume: 40 | Issue: 11 | Pages: 2169-2181

10.1093/ndt/gfaf111 | PMID 40586687 Get It

ABSTRACT Background This medical center migrated from alcohol to sotradecol foam sclerotherapy (SFS) because of perceived improved efficacy in managing symptomatic kidney and liver cysts. We report technical aspects, change in short- and long-term cyst volumes, patient-reported outcomes, safety and applications of the technique. Methods In this retrospective observational study, cases from January 2017 to December 2021 had TKCV/TLCV (per Targeted Kidney or Liver or Cyst analysis) segmented using a deep-learning algorithm and cyst segmentation software (pre-, post-procedure and longitudinally). TKCV/TLCV % change were evaluated using the one-sample Wilcoxon signed rank test. For analyses involving changes in cyst volumes, the median % change in cyst volume per patient was assessed. Longitudinal changes in cyst volumes were assessed using linear mixed models. Changes in quality of life (QOL) [Linear Analog Self-Assessment (LASA), Polycystic Liver Disease Quality of life Questionnaire (PLD-Q) and 12-item short-form (SF12)] were also assessed. Results There were 102 SFS sessions (38 kidney, 58 liver, 6 combined liver/kidney cysts) performed on 77 unique individuals included for analysis. Median [interquartile range (IQR)] % reductions in TKCV were –92.0% (IQR –98.2%, –82.7%, P &lt; .001) and for TLCV were –83.1% (IQR –93.5%, –52.9%, P &lt; .001). Among patients with multiple kidney procedures (n = 7), median % reduction in TKCV was –94.3% (IQR –96.6%, –92.4%, P = .023). For patients with multiple liver procedures (n = 11), median % reduction in TLCV was –63.3% (IQR –85.2%, –28.3%, P = .004). Results were similar among the four patients undergoing multi-stage procedures (n = 1 kidney, n = 3 liver). When measured longitudinally, both liver and kidney cyst volumes declined to levels near 0 mL by 1 year follow-up and remained stable several years later. LASA physical domain and PLD-Q QOL scores improved post-SFS procedure. Conclusion SFS led to substantial long-term reductions in TKCV/TLCV and improved QOL. SFS can augment cyst volume reduction in addition to tolvaptan (kidney cysts) and octreotide (liver cysts). In some individuals with large symptomatic cysts, multiple SFS procedures were safe and effective in reducing TLCV/TKCV and improving symptoms.